Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T pro…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.03 | $0.21 | $12.27 |
| Estimado | $0.23 | $-11.50 | $-0.97 | $-0.07 |
| Sorpresa | — | +100.3% | +121.6% | +17628.6% |
| Métrica | LKFT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 97.3% | 57.4% | +39.9% |
| Operating Margin | 26.5% | -34.4% | +60.9% |
| Net Margin | 28.9% | -32.5% | +61.3% |
| FCF Margin | -24.4% | -12.6% | -11.8% |
| ROE | 9.9% | -39.2% | +49.1% |
| ROA | 9.4% | -30.9% | +40.4% |
| Current Ratio | 20.15 | 2.73 | +17.42 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 9.4% | — |
| ✗Flujo de caja operativo positivo | −€257M | −€320M |
| ✓Rentabilidad sobre activos al alza | 9.4% | 1.8% |
| ✗Caja operativa/activos supera al ROA | -7.6% | ROA 9.4% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 20.15 | 9.97 |
| ✓Sin aumentar el nº de acciones | 66M | 66M |
| ✓Margen bruto al alza | 97.3% | 87.4% |
| ✓Rotación de activos al alza | 0.33 | 0.07 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -24.4% |
| ✗ROCE > 10 % | 9.1% |
| ✓Ventas > 5 %/año (3 años) | 66.4% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 42.5% |
Riesgo de quiebra (Altman Z 7.8): zona segura
Lakefront Biotherapeutics NV cotiza a 29.90 USD y tiene una capitalización bursátil de $2.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud